PFS benefit (BICR) was observed in patients with tumor-cell PD-L1 ≥ 1% with NIVO + Chemo versus Chemo (median PFS, 7.0 vs. 4.2 months; HR 0.56 [0.36–0.89]) (Fig. 2c). The gene discussed is CD274; the disease is neoplasm.